EDEN PRAIRIE, Minn., May 05, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that CFO Ron McClurg will present at the Sidoti Micro-Cap Virtual Conference being held May 10-11, 2023.
| Presentation date: | Wednesday, May 10, 2023 |
| Presentation time: | 10:45 a.m.* |
| Registration: | sidoti.com/events |
| Live presentation: | Session link |
| 1x1 meetings: | Investors may request meetings by contacting their Sidoti representative or NeuroOne Investor Relations. |
*Please note that the presentation date and time are subject to change. Attendees may refer to the program agenda for more information.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
*Caution: Federal law restricts this device to sale by or on the order of a physician.
Contact:
800-631-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.83 |
| Daily Change: | -0.08 -8.33 |
| Daily Volume: | 23,815 |
| Market Cap: | US$25.700M |
October 31, 2024 September 10, 2024 September 05, 2024 August 14, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
